# Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Study · id `cardio:ct-nct06563895` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06563895](<https://clinicaltrials.gov/study/NCT06563895>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06563895

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 587 participants.

## Technical summary

Registry record NCT06563895. Randomized; quadruple masking; primary purpose prevention. Start 2025-05-12 (actual); primary completion 2031-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 587 participants (planned count; ClinicalTrials.gov record NCT06563895, source copy `cardio:ctgov-nct06563895-2026-08-04`, retrieved 2026-10-31)
- Started: 2025-05-12 (actual) (ClinicalTrials.gov record NCT06563895, source copy `cardio:ctgov-nct06563895-2026-08-04`, retrieved 2026-10-31)
- Primary completion: 2031-10 (anticipated) (ClinicalTrials.gov record NCT06563895, source copy `cardio:ctgov-nct06563895-2026-08-04`, retrieved 2026-10-31)
- Completion: 2032-12 (anticipated) (ClinicalTrials.gov record NCT06563895, source copy `cardio:ctgov-nct06563895-2026-08-04`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; Denmark; France; Germany; Greece; Ireland; Italy; Japan; Malaysia; Martinique; Mexico; Netherlands; Portugal; Singapore; South Korea; Spain; Sweden; Taiwan; United Kingdom (ClinicalTrials.gov record NCT06563895, source copy `cardio:ctgov-nct06563895-2026-08-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06563895-2026-08-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Condition: Amyloidosis
- Condition: Amyloid Cardiomyopathy
- Condition: Transthyretin Amyloidosis
- Condition: Cardiomyopathies
- Condition: Heart Diseases
- Condition: Polyneuropathies
- Intervention (Drug): Acoramidis
- Intervention (Drug): Placebo oral tablet
- Lead sponsor: Eidos Therapeutics, a BridgeBio company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Eidos Therapeutics, a BridgeBio company (`cardio:org-eidos-therapeutics-a-bridgebio-company`)

## Provenance

Content hash: 91c63a0f6092760258a4a5f246182139e6b90d04fe3493985c96c16dfa15fa01
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
